Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 93 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kura Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KURA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Kura Oncology stock price (NASDAQ: KURA)Use our graph to track the performance of KURA stocks over time.
Kura Oncology shares at a glance
|Latest market close||$22.25|
|52-week range||$16.39 - $43.00|
|50-day moving average||$20.42|
|200-day moving average||$26.58|
|Wall St. target price||$43.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.57|
Buy Kura Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kura Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kura Oncology price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||5.25%|
|3 months (2021-05-03)||-16.79%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Kura Oncology financials
|Gross profit TTM||$0|
|Return on assets TTM||-15.15%|
|Return on equity TTM||-25.62%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
Shorting Kura Oncology shares
There are currently 8.1 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 5.5% down from 8.5 million last month.
There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.
Kura Oncology's "short interest ratio" (SIR)
Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 769025.21489971). Kura Oncology's SIR currently stands at 10.47. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 10470 shares are currently held short.
However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 120 shares are currently held short) or 0.1424% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 142 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kura Oncology.
Find out more about how you can short Kura Oncology stock.
Kura Oncology share dividends
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Kura Oncology share price volatility
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $16.39 up to $43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 1.895. This would suggest that Kura Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kura Oncology overview
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Stocks similar to Kura Oncology
Kura Oncology in the news
Kura Oncology to Report Second Quarter 2021 Financial Results
Kura Oncology to Report Second Quarter 2021 Financial Results
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
Frequently asked questionsWhat percentage of Kura Oncology is owned by insiders or institutions?
Currently 2.691% of Kura Oncology shares are held by insiders and 105.513% by institutions. How many people work for Kura Oncology?
Latest data suggests 93 work at Kura Oncology. When does the fiscal year end for Kura Oncology?
Kura Oncology's fiscal year ends in December. Where is Kura Oncology based?
Kura Oncology's address is: 12730 High Bluff Drive, San Diego, CA, United States, 92130 What is Kura Oncology's ISIN number?
Kura Oncology's international securities identification number is: US50127T1097 What is Kura Oncology's CUSIP number?
Kura Oncology's Committee on Uniform Securities Identification Procedures number is: 50127T109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert